Detecting Recurrent Prostate Cancer With 11C-choline Positron Emission Tomography

Inclusion Criteria:

Patient must have biopsy-proven adenocarcinoma of the prostate initially treated with curative intent (surgery and radiation therapy are most common treatments but other treatments are also eligible).

Biochemical recurrence defined as any of the following:

PSA ≥ 0.2 ng/mL in at least two sequential tests for patients treated with surgery.
PSA ≥ 0.2 ng/mL above the post therapy nadir for patients treated with radiation therapy, brachytherapy or cryotherapy.
PSA ≥ 0.2 ng/ml above the most recent therapy nadir for patients who have received additional treatment in the recurrent setting
Patient must have undergone standard-of-care restaging that does not clearly identify site(s) of active disease, or such prior studies must show equivocal findings for which further work-up is considered necessary to make clinical decision. Standard staging examinations may include one or more of the following: CT or MRI, bone imaging (either Tc-99m bisphosphonate scintigraphy MDP or F-18 sodium fluoride PET), FDG PET, or In-111 capromab pendetide scintigraphy no older than 3 months of consent date.
Age ≥ 18 years.
Patient must be able to tolerate PET/CT imaging.
Patient must be able to understand and willing to sign a written informed consent document.

Exclusion Criteria:

Patient must not have claustrophobia that would preclude PET/CT imaging or other contraindications to CT imaging.